-
Raltegravir (RAL) received FDA approval in 2007 and is now used in treatment of both treatment-experienced and treatment-naïve patients.
-
A 52-year-old woman had systemic symptoms including nausea and vomiting. Seven months prior to admission she had a subarachnoid hemorrhage and needed multiple ventriculo-pleural shunts.
-
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
The National Health Service in Britain in 2007 elected to ban traditional white coats and other long-sleeved garments for physicians in the workplace (including long-sleeved blouses and shirts).
-
Despite the recent gains achieved by multidisciplinary control programs, malaria still kills nearly 1 million people and causes almost 300 million symptomatic illnesses globally per year, with most of this burden borne by sub-Saharan Africa.
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
Coccidioidal infections are always unique the travel history often provides the right clue for the practitioner but first you have to think to ask the right question.
-
Due to heightened surveillance of acute febrile illness in China, a severe illness associated with thrombocytopenia and multi-system organ involvement was recognized beginning in 2009.
-
The Association for Professionals in Infection Control and Epidemiology (APIC) is tracking a growing body of proposed state legislation related to infection prevention in long term care. A selection of state bills proposed this year include the following: